The use of biopharmaceuticals dates from the 19th century and within 5-10 years, up to 50%
of all drugs in development will be biopharmaceuticals. In the 1980s, the biopharmaceutical …

ABSTRACT L-asparaginase (EC 3.5. 1.1) is an enzyme that catalysis mainly the asparagine
hydrolysis in L-aspartic acid and ammonium. This enzyme is presented in different …

L-Asparaginase (ASNase) is a vital component of the first line treatment of acute
lymphoblastic leukemia (ALL), an aggressive type of blood cancer expected to afflict over …

Abstract l‐Asparaginase (EC 3.5. 1.1.) is a vital enzyme that hydrolyzes l‐asparagine to l‐
aspartic acid and ammonia. This property of l‐asparaginase inhibits the protein synthesis in …

Microbial L-asparaginase (ASNase) is an important anticancer agent that is used
extensively worldwide. In this study, 40 bacterial isolates were obtained from the Red Sea of …

In the past decades, the production of biopharmaceuticals has gained high interest due to its
great sensitivity, specificity, and lower risk of negative effects to patients. Biopharmaceuticals …

Abstract L-Asparaginase (L-ASNase, EC 3.5. 1.1), an antitumor drug for acute lymphoblastic
leukemia (ALL) therapy, is widely used in the clinical field. Similarly, L-ASNase is also a …

l-Asparaginase (EC 3.5. 1.1) was first used as a component of combination drug therapies to
treat acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow, almost 50 …

Immunotherapy is a milestone in the treatment of poor-prognosis pediatric acute
lymphoblastic leukemia (ALL) and is expected to improve treatment outcomes and reduce …

L-asparaginase is a vital enzyme of medical importance, and renowned as a
chemotherapeutic agent. The relevance of this enzyme is not only limited as an anti-cancer …